Drug for preventing or treating allergic diseases
By developing antibodies that target the Ibp protein of Lachnospiraceae family bacteria to inhibit IgE binding, the treatment of allergic diseases is enhanced, addressing the limitations of existing therapies and reducing side effects, offering a more effective and safer approach to managing allergic reactions.
Patent Information
- Application Number
- PCT/JP2024/020020
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for allergic diseases, such as antihistamines and anti-IgE antibodies like omalizumab, have side effects and limited effectiveness, and the pathogenesis of allergies is not fully understood, particularly in relation to intestinal microbiota like Ruminococcus gnavus which promotes allergic reactions.
Development of antibodies or antibody derivatives that bind to the Ibp protein of Lachnospiraceae family bacteria, specifically targeting the C-terminal region involved in IgE binding, to inhibit the interaction between Ibp proteins and IgE, thereby suppressing allergic reactions without directly binding to IgE, thus reducing side effects and enhancing treatment efficacy.
The antibodies or antibody derivatives effectively inhibit the binding between Ibp proteins and IgE, reducing histamine production and allergic reactions, providing a more targeted and safer approach to preventing and treating allergic diseases like atopic dermatitis and respiratory allergies.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure 00000032_0000
Abstract
Description
Drugs for preventing and treating allergic diseases
[0001] The present invention relates to the development of pharmaceuticals for preventing or treating allergic diseases, and more specifically to the development of antibody pharmaceuticals for preventing or treating allergic diseases.
[0002] Allergies occur when allergens (antigens), substances that cause allergies such as those derived from food, pollen, and dust mites, enter the body, causing the production of IgE antibodies (sensitization).When the allergen enters the body again, the IgE antibodies react, causing the mast cells to release chemical messengers such as histamine, which causes the symptoms of allergic disease.
[0003] Although the mechanism of allergy onset remains largely unknown, its relationship with the intestinal microbiota has recently been attracting attention. Studies of pediatric allergy patients have shown that Ruminococcus gnavus (Mediterraneibacter gnavus) (hereinafter referred to as "R. gnavus") increases in the intestines, and experiments in which R. gnavus was administered to mice have shown that administration of this bacterium is associated with and promotes the onset of allergic diseases, particularly respiratory allergies (Non-Patent Document 1).
[0004] Antihistamines are commonly used to treat allergies, but they can cause side effects such as drowsiness and their effectiveness can decrease with continued use. The anti-IgE antibody omalizumab (trade name: Xolair) is also available commercially as an antibody-based allergy treatment. Xolair binds to human IgE and inhibits the binding of human IgE to IgE receptors, thereby suppressing allergic reactions. Xolair targets the human IgE antibody itself, which carries the risk of anaphylactic reactions as a serious side effect. It also reduces the amount of IgE in the blood, raising concerns that it may affect the host's immune defense mechanisms mediated by IgE, such as against parasitic infections.
[0005] Under these circumstances, it was discovered that the Ibp proteins of bacteria from the Lachnospiraceae family, including the enterobacterium R. gnavus, are involved in the development of allergic diseases, and the pathogenesis of allergic diseases involving the Ibp proteins of Lachnospiraceae bacteria was elucidated (Patent Document 1). It was also shown that administering or producing in vivo substances that bind to the Ibp proteins of Lachnospiraceae bacteria can prevent allergic disease reactions occurring in vivo (Patent Document 1).
[0006] The binding of R. gnavus to IgA was originally investigated, and it was reported that the immunoglobulin-binding proteins (Ibp), IbpA and IbpB, contained in R. gnavus bind to human and mouse IgA as superantigens, and that these superantigens act on B cells to increase IgA production (Non-patent Document 2).
[0007] Patent application 2021-195941
[0008] Chua, et al., Gastroenterology. 154: 154-167, 2018Bunker, et al., Sci Transl Med, 11, eaau9356, 2019
[0009] Based on the previous finding that substances that bind to the Ibp protein of bacteria of the Lachnospiraceae family can prevent allergic disease reactions that occur in the body, the objective of the present invention is to develop substances that can prevent or treat allergic diseases and pharmaceutical compositions containing such substances.
[0010] The inventors of the present invention have demonstrated that it is possible to prepare antibodies or antibody derivatives that do not directly bind to IgE but bind to a region of the Ibp protein produced by Lachnospiraceae bacteria, an enterobacterium associated with allergic diseases, that is important for IgE binding, and to provide pharmaceutical compositions for preventing or treating allergic diseases, comprising such antibodies or antibody derivatives.
[0011] More specifically, to solve the above-mentioned problems, the present application provides the following aspects: [1]: (1) An antibody or antibody derivative having binding activity to an Ibp antigen, comprising heavy chain and light chain complementarity determining regions: heavy chain complementarity determining regions, CDR1 (GFTFSNYGMA, SEQ ID No.: 1), CDR2 (TISYDGSSTYYRDSVKG, SEQ ID No.: 2), and CDR3 (ESFGTTVVPHYFDY, SEQ ID No.: 3), and light chain complementarity determining regions, CDR1 (QASQDIGNWLS, SEQ ID No.: 4), CDR2 (GATSLAD, SEQ ID No.: 5), and CDR3 (LQAYSAPWT, SEQ ID No.: 6); [2]: The antibody or antibody derivative according to [1], wherein the antibody or antibody derivative is human; [3]: The antibody or antibody derivative according to [2], wherein the human antibody derivative is a modified human antibody or a functional fragment thereof selected from a humanized antibody, a chimeric antibody, a multivalent antibody, and a multispecific antibody; [4]: The antibody or antibody derivative according to [3], wherein the functional fragment is Fab, Fab', F(ab')2, a single-chain variable region fragment (scFv), or a disulfide-stabilized (dsFv) antibody; [5]: The antibody or human antibody derivative according to [3], wherein the heavy chain variable region VH domain of the antibody or human antibody derivative having binding ability to an Ibp antigen has the amino acid sequence of (VH-1-1) EVMLVESGGG LVQPGRSMKL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNAKSTLY LQMNSLRSED TATYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 7), or the amino acid sequence of SEQ ID NO: 7 amino acid sequences containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in portions other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3); (VH-1-2) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTIthe amino acid sequence of SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 9), or an amino acid sequence of SEQ ID NO: 9 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion of the amino acid sequence of SEQ ID NO: 9 other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3); (VH-1-3) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI the amino acid sequence of SRDNSKNTLY LQMNSLRSED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 10), or an amino acid sequence of SEQ ID NO: 10 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion of the amino acid sequence of SEQ ID NO: 10 other than CDR1 (SEQ an amino acid sequence of SEQ ID NO: 11, or an amino acid sequence of SEQ ID NO: 11, except for CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3), which contains one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions; (VH-1-4) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 11), or an amino acid sequence of SEQ ID NO: 11, which contains one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion of the amino acid sequence of SEQ ID NO: 11, except for CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3); [6]: The antibody or antibody derivative according to [1] or [2], selected from the group consisting of: [6]: The antibody or humanized antibody derivative having binding activity to an Ibp antigen, wherein the amino acid sequence of the light chain variable region VL domain is: (VL-1-1) DIQMTQSPAS LSASLEEIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYGthe amino acid sequence of ATSLADGVPS RFSGSRSGTQ YSLKISRLQV EDIGIYYCLQ AYSAPWTFGG GTKLELK (SEQ ID NO: 8), or the amino acid sequence of SEQ ID NO: 8 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); (VL-1-2) DIQMTQSPSS LSASVGDRVT ITCQASQDIG NWLSWYQQKP GKSPKLLIYG ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 12), or the amino acid sequence of SEQ ID NO: 12 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: an amino acid sequence containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); (VL-1-3) DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 13), or an amino acid sequence of SEQ ID NO: 13 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTQ YTLTISSLQP EDIATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 14), or the amino acid sequence of CDR1 (SEQ ID NO:an amino acid sequence containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); [7]: the antibody or antibody derivative according to either [1] or [2], which binds to Ibp and inhibits the binding of Ibp to IgE in vivo; [8]: the antibody or antibody derivative according to [7], for preventing or treating an allergic disease; [9]: the antibody or antibody derivative according to [8], wherein the allergic disease is atopic dermatitis;
[10] : (1) the heavy chain complementarity determining regions, CDR1 (GFTFSNYGMA, SEQ ID No.: 1), CDR2 (TISYDGSSTYYRDSVKG, SEQ ID No.: 2), and CDR3 (ESFGTTVVPHYFDY, SEQ ID No.: 3), and A pharmaceutical composition for preventing or treating an allergic disease, comprising an antibody or antibody derivative having binding activity to an Ibp antigen, the antibody or antibody derivative comprising the heavy and light chain complementarity determining regions of: a light chain complementarity determining region, CDR1 (QASQDIGNWLS, SEQ ID No.: 4), CDR2 (GATSLAD, SEQ ID No.: 5), and CDR3 (LQAYSAPWT, SEQ ID No.: 6);
[11] : The pharmaceutical composition for preventing or treating an allergic disease according to
[10] , wherein the antibody or antibody derivative is human;
[12] : The pharmaceutical composition for preventing or treating an allergic disease according to
[11] , wherein the allergic disease is atopic dermatitis.
[0012] Based on the previous finding that in vivo allergic reactions can be prevented by substances that bind not directly to IgE but to a region important for IgE binding in the Ibp protein of Lachnospiraceae bacteria (e.g., Ruminococcus bacteria), an enterobacterium associated with allergic diseases, the present invention provides an antibody or antibody derivative that binds to the Ibp protein of Lachnospiraceae bacteria or a variant thereof and can prevent or treat in vivo allergic reactions. The antibody or antibody derivative can suppress allergic reactions by exerting an inhibitory effect on allergens. Therefore, it does not bind to human IgE and suppresses allergic reactions without inhibiting the host's immune system, thereby reducing the problem of side effects.
[0013] Figure 1 shows a schematic diagram of various fragments of Ibp protein prepared to investigate the binding mode between Ibp protein and IgE. Figure 2 shows the in vitro activity of antibodies Clone A and Clone B selected in the present invention to inhibit the binding of Ibp protein to IgE. Figure 3 shows an outline of the experimental protocol used to investigate the effect of anti-Ibp antibodies on the in vivo inhibition of the binding of human IgE to Ibp. Figure 4 shows the results of an investigation into whether antibody Clone A exhibits an allergy-suppressing effect in SPF mice in vivo.
[0014] The present invention is based on the previous finding that substances that bind to the Ibp protein of Lachnospiraceae bacteria can prevent allergic reactions that occur in the body. The present invention aims to eliminate the side effects of antihistamines, which are commonly used in the treatment of allergic diseases, and the anti-IgE antibody omalizumab (trade name: Xolair), which is also used in the treatment of allergic diseases. Based on this finding, the present invention has demonstrated that, as a new therapeutic tool for allergic diseases, antibodies or antibody derivatives can be produced as substances that bind not directly to IgE but to a region important for IgE binding in the Ibp protein produced by Lachnospiraceae bacteria, an intestinal bacterium associated with allergic diseases, and that pharmaceutical compositions for preventing or treating allergic diseases can be provided, comprising such antibodies or antibody derivatives.
[0015] Specifically, in one aspect, the present invention provides an antibody or antibody derivative that has binding affinity to an Ibp antigen and comprises heavy and light chain complementarity-determining regions (CDR1 to CDR3) represented by specific amino acid sequences.
[0016] In previous studies, the inventors of the present invention have shown that the Ibp protein of Ruminococcus bacteria causes allergic diseases by binding to IgE (Patent Document 1). Specifically, they have shown that the Ibp protein of Lachnospiraceae bacteria, more specifically, the genus Ruminococcus among Lachnospiraceae bacteria, and even more specifically, the Ibp protein derived from Ruminococcus gnavus (R. gnavus) among Ruminococcus bacteria, binds to IgE in vivo and induces histamine production from mast cells, resulting in allergies.
[0017] On the other hand, the inventors of the present invention have also shown that by inhibiting the non-specific binding of the Ibp protein or its variants of Lachnospiraceae bacteria to IgE in the body, it is possible to inhibit histamine production from mast cells, and consequently inhibit the onset of allergic diseases (Patent Document 1).
[0018] Ibp proteins are immunoglobulin-binding proteins found in R. gnavus, and R. gnavus Ibp proteins have two homologs, IbpA and IbpB. R. gnavus IbpA has 607 amino acids (WP_105084811.1), and IbpB has 625 amino acids (WP_105084812.1). Both proteins contain a signal peptide (SP), variable region (VR), conserved repeat sequences, and Ig-binding domains (Figure 1) from the N-terminus. The Ig-binding domain in the C-terminal region of Ibp proteins is known to give them the ability to nonspecifically bind to mouse IgG, IgM, and IgA.
[0019] The present inventors previously prepared ibp gene fragments of various lengths using R. gnavus genomic DNA (NCBI Reference Sequence: NZ_CP027002.1) as a template, and then prepared various truncated Ibp proteins based on these fragments to examine the regions involved in IgE binding. The results revealed that the repeat region proteins, consisting of amino acids 111 to 378 of the IbpA protein (WP_105084811.1) or 126 to 393 of the IbpB protein (WP_105084812.1), and the C-terminal region proteins, consisting of amino acids 379 to 574 (ibpA C200) of the IbpA protein (WP_105084811.1) or 394 to 592 (ibpB C200) of the IbpB protein (WP_105084812.1), are involved in IgE binding.
[0020] Based on these results, it is preferable that the antibody or antibody derivative of the present invention binds to a structural region of the Ibp protein of a Lachnospiraceae bacterium that is involved in the binding of the Ibp protein to IgE. Examples of such a structure on the Ibp protein include the C-terminal region of the IbpA protein (WP_105084811.1) or the IbpB protein (WP_105084812.1). Examples of the C-terminal region of the IbpA protein (WP_105084811.1) or the IbpB protein (WP_105084812.1) include the C-terminal region of the amino acid sequence from amino acid numbers 379 to 574 of the IbpA protein (WP_105084811.1) or from amino acid numbers 394 to 592 of the IbpB protein (WP_105084812.1).
[0021] Since the antibody or antibody derivative of the present invention is intended to inhibit the binding of Ibp proteins to IgE in vivo, it is preferable that it binds to the C-terminal region of these Ibp proteins, thereby inhibiting the binding of Ibp proteins to IgE in vivo.
[0022] The antibodies or antibody derivatives of the present invention having the above-mentioned characteristics can be provided as antibodies or antibody derivatives comprising heavy and light chain complementarity determining regions (CDR1 to CDR3) represented by specific amino acid sequences, including: (1) heavy chain complementarity determining regions, CDR1 (GFTFSNYGMA, SEQ ID No.: 1), CDR2 (TISYDGSSTYYRDSVKG, SEQ ID No.: 2), and CDR3 (ESFGTTVVPHYFDY, SEQ ID No.: 3), and light chain complementarity determining regions, CDR1 (QASQDIGNWLS, SEQ ID No.: 4), CDR2 (GATSLAD, SEQ ID No.: 5), and CDR3 (LQAYSAPWT, SEQ ID No.: 6).
[0023] The antibodies or antibody derivatives containing these heavy and light chain variable regions bind to the C-terminal region of Ibp proteins and, as a result, have the activity of inhibiting the binding of Ibp proteins to IgE in vivo. Because of this activity, the antibodies or antibody derivatives of the present invention can be used to prevent or treat allergic diseases.
[0024] Among the antibodies or antibody derivatives of the present invention, the monoclonal antibody obtained as Clone A, which has binding activity to the Ibp antigen, was found to have the amino acid sequence of the heavy chain variable region VH domain: (VH-1-1) EVMLVESGGG LVQPGRSMKL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNAKSTLY LQMNSLRSED TATYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 7).
[0025] According to general knowledge regarding the amino acid sequence structure of antibodies, the amino acid sequence of the heavy chain variable region VH domain other than the sequences of CDR1 to CDR3 is allowed to be variable. Therefore, the amino acid sequence of the above-mentioned (VH-1-1) other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3) is allowed to contain one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions.
[0026] Specifically, the present invention provides an antibody or humanized antibody derivative that has binding ability to an Ibp antigen, wherein the amino acid sequence of the heavy chain variable region VH domain of the antibody or humanized antibody derivative is the amino acid sequence of (VH-1-1) EVMLVESGGG LVQPGRSMKL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNAKSTLY LQMNSLRSED TATYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 7), or an amino acid sequence of SEQ ID NO: 7 that contains one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3).
[0027] The antibody or antibody derivative of the present invention may have a heavy chain variable region VH domain having the same complementarity determining regions (CDRs) as the heavy chain variable region VH domain of Clone A having the above-mentioned Ibp antigen-binding activity but having different framework regions (FRs), and the amino acid sequences of the heavy chain variable region VH domains are as follows: (VH-1-2) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRSED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 9); (VH-1-3) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRSED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 10); (VH-1-4) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 11).
[0028] As described above, variability is permitted in the amino acid sequence of the heavy chain variable region VH domain other than the sequences of CDR1 to CDR3. Of the amino acid sequences of (VH-1-2) to (VH-1-4) described above, the portions other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3) are permitted to contain one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions.
[0029] That is, the present invention provides an antibody or humanized antibody derivative having binding activity to an Ibp antigen, wherein the amino acid sequence of the heavy chain variable region VH domain is the amino acid sequence of (VH-1-2) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 9), or an amino acid sequence of SEQ ID NO: 9 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3); or (VH-1-3) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA an amino acid sequence of PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRSED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 10), or an amino acid sequence of SEQ ID NO: 10 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3); (VH-1-4) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 11), or an amino acid sequence of SEQ ID NO: 11 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion of the amino acid sequence of SEQ ID NO: 11 other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3);An antibody or antibody derivative selected from the group consisting of:
[0030] Among the antibodies or antibody derivatives of the present invention, the monoclonal antibody obtained as Clone A, which has binding activity to the Ibp antigen, was found to have the amino acid sequence of the light chain variable region VL domain: (VL-1-1) DIQMTQSPAS LSASLEEIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTQ YSLKISRLQV EDIGIYYCLQ AYSAPWTFGG GTKLELK (SEQ ID NO: 8).
[0031] Based on general knowledge regarding the amino acid sequence structure of antibodies, the amino acid sequence of the light chain variable region VL domain other than the sequences of CDR1 to CDR3 is allowed to be variable. Therefore, the amino acid sequence of the above-mentioned (VL-1-1) other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6) is allowed to contain one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions.
[0032] Specifically, the present invention provides an antibody or humanized antibody derivative that has binding ability to an Ibp antigen, wherein the amino acid sequence of the light chain variable region VL domain of the antibody or humanized antibody derivative is the amino acid sequence of (VL-1-1) DIQMTQSPAS LSASLEEIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTQ YSLKISRLQV EDIGIYYCLQ AYSAPWTFGG GTKLELK (SEQ ID NO: 8), or an amino acid sequence of SEQ ID NO: 8 that contains one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6).
[0033] The antibody or antibody derivative of the present invention may have a light chain variable region VL domain having the same complementarity determining regions (CDRs) as the light chain variable region VL domain of Clone A having the above-mentioned Ibp antigen-binding activity but having different framework regions (FRs), and the amino acid sequences of the light chain variable region VL domains are as follows: (VL-1-2) DIQMTQSPSS LSASVGDRVT ITCQASQDIG NWLSWYQQKP GKSPKLLIYG ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 12); (VL-1-3) DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 13). (VL-1-4) DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTQ YTLTISSLQP EDIATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 14).
[0034] As described above, the amino acid sequence of the light chain variable region VL domain is permissible for variability in the sequence other than CDR1 to CDR3, and the amino acid sequences of (VL-1-2) to (VL-1-4) described above are permissible for variability in the sequence other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6), and are permissible for variability in the sequence of one or more amino acids (e.g., conservative substitutions), insertions, or deletions.
[0035] That is, the present invention provides an antibody or humanized antibody derivative having binding activity to an Ibp antigen, wherein the amino acid sequence of the light chain variable region VL domain is the amino acid sequence of: (VL-1-2) DIQMTQSPSS LSASVGDRVT ITCQASQDIG NWLSWYQQKP GKSPKLLIYG ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 12), or an amino acid sequence of SEQ ID NO: 12 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); (VL-1-3) DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP an amino acid sequence of GKSPQLLIYG ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 13), or an amino acid sequence of SEQ ID NO: 13 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); (VL-1-4) DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTQ YTLTISSLQP EDIATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 14), or an amino acid sequence of SEQ ID NO: An antibody or antibody derivative selected from the group consisting of: an amino acid sequence containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6) among the 14 amino acid sequences can also be provided.
[0036] The antibody or human antibody derivative capable of binding to the Ibp antigen that can be used in the present invention may be an antibody or human antibody derivative formed from any combination of the heavy chain variable region VH domain and light chain variable region VL domain described above, i.e., a combination of any of the VH domains (VH-1-1) to (VH-1-4) and any of the VL domains (VL-1-1) to (VL-1-4). More specifically, the antibodies can be: a rat antibody; a chimeric antibody; or a humanized antibody; a humanized antibody; a humanized antibody; or a chimeric antibody; or ...
[0037] The antibodies or antibody derivatives of the present invention can be made into human antibody derivatives while maintaining the above-mentioned sequences of CDR1 to CDR3 of the heavy and light chains, based on known techniques generally related to antibodies or antibody derivatives. Such human antibody derivatives can be selected from humanized antibodies, chimeric antibodies, multivalent antibodies, and multispecific antibodies, or functional fragments thereof. Here, the functional fragments of antibodies or antibody derivatives include Fab, Fab', F(ab')2, single-chain variable region fragments (scFv), disulfide-stabilized (dsFv) antibodies, etc.
[0038] In the present invention, it has been demonstrated that the above-described antibodies or antibody derivatives can inhibit the binding of Ibp proteins to IgE in vivo, thereby suppressing histamine secretion from mast cells. This indicates that the occurrence of allergic diseases in vivo can be prevented or treated. Therefore, in another aspect of the present invention, there is provided an invention relating to the pharmaceutical use of antibodies or antibody derivatives of the present invention having the above-described characteristics, which comprise heavy and light chain complementarity-determining regions (CDR1-CDR3) represented by specific amino acid sequences.
[0039] Specifically, the present invention provides: (1) a pharmaceutical composition for preventing or treating an allergic disease, comprising an antibody or antibody derivative having binding activity to an Ibp antigen, the antibody or antibody derivative comprising heavy chain complementarity determining regions, CDR1 (GFTFSNYGMA, SEQ ID No.: 1), CDR2 (TISYDGSSTYYRDSVKG, SEQ ID No.: 2), and CDR3 (ESFGTTVVPHYFDY, SEQ ID No.: 3), and light chain complementarity determining regions, CDR1 (QASQDIGNWLS, SEQ ID No.: 4), CDR2 (GATSLAD, SEQ ID No.: 5), and CDR3 (LQAYSAPWT, SEQ ID No.: 6); and
[0040] Alternatively, the invention of the pharmaceutical use of the above-mentioned antibody or antibody derivative in the present invention can also be described as: a method for preventing or treating allergic diseases by administering the above-mentioned antibody or antibody derivative; the above-mentioned antibody or antibody derivative for use in preventing or treating allergic diseases; use of the above-mentioned antibody or antibody derivative in the manufacture of a medicament for preventing or treating allergic diseases.
[0041] The antibody or antibody derivative of the present invention binds to the IgE-binding region on the Ibp protein of Lachnospiraceae bacteria, competing with IgE to prevent IgE from binding to the Ibp protein, thereby inducing IgE-mediated stimulation of mast cells and inhibiting the production and release of histamine from mast cells. Due to this mechanism of action, the antibody or antibody derivative of the present invention can be used for the prevention of allergic diseases in addition to their therapeutic use. Allergic diseases often develop symptoms due to unintended sensitization to allergens, and therefore, in clinical settings, their use is desirable not only for symptomatic treatment but also for preventative purposes.
[0042] The antibodies or antibody derivatives used in the pharmaceutical applications of the present invention may be those having the characteristics already described above, and are preferably human antibodies or antibody derivatives, particularly when administered to humans.
[0043] Allergic diseases that can be prevented or treated with the antibody or antibody derivative of the present invention include bronchial asthma, atopic dermatitis, allergic rhinitis, hay fever, food allergy, and allergic conjunctivitis, of which atopic dermatitis is particularly sought after as an allergic disease that can be prevented or treated with the antibody or antibody derivative of the present invention.
[0044] When the antibodies or antibody derivatives of the present invention are used for pharmaceutical purposes, they can be administered via common routes such as intradermal, subcutaneous, intramuscular, intravenous, oral, or intraperitoneal administration. Because the Lachnospiraceae bacteria that produce the target Ibp protein are enterobacteria, they can also be administered via routes such as rectal administration. By using an appropriate drug delivery system (DDS), they can also be administered via other routes.
[0045] The present invention will be specifically illustrated by the following examples, which are not intended to limit the present invention in any way.
[0046] Example 1: Obtaining anti-Ibp antibodies Previous studies have revealed that the C-terminal region of Ibp plays an important role in the binding of Ibp to IgE (Patent Document 1). Therefore, we thought that creating antibodies targeting the C-terminus of Ibp would lead to the development of new therapies for allergic diseases, and so we produced monoclonal antibodies. In this example, we first produced anti-Ibp monoclonal antibodies.
[0047] Rats were immunized with a truncated protein (IbpA C200, amino acids 375-574 of WP_105084811.1) common to IbpA and IbpB to generate monoclonal antibodies. Two female Wistar rats were immunized subcutaneously with 0.1 mg of antigen twice, followed by a final subcutaneous booster dose of 0.04 mg of antigen. After three days, spleen cells were isolated from each of the three rats, and B cells were harvested. Hybridomas were generated by cell fusion between these B cells and mouse myeloma cells (P3U1).
[0048] The resulting hybridomas were cultured in 2 mL of culture medium (RPMI1640, penicillin-streptomycin-glutamine solution, sodium pyruvate, 10% FBS) in a 24-well cell culture plate for 4-7 days (1 mL per clone per well, enough for 2 wells). The culture supernatant was then collected and screened by ELISA using IbpA C200 to identify positive wells. Cells from the positive wells were cloned by limiting dilution, and this process was repeated twice to obtain 180 hybridoma clones.
[0049] For monoclonal antibodies against IbpA C200, 180 clones reactive with IbpA C200 were obtained in the primary screening. To select useful clones from these 180 clones, we performed the following tests: (1-1) FACS binding assay for wild-type Ruminococcus gnavus (WT Rg) and R. gnavus lacking ΔIbpAB (ΔIbpAB Rg), (1-2) ELISA assay for binding to IbpA C200, IbpA N200, and IbpA CR, and (1-3) LAD2 cell histamine production inhibitory activity. These tests were performed using hybridoma supernatants derived from the 180 clones.
[0050] (1-1) Evaluation of binding to wild-type Ruminococcus gnavus (WT Rg) and R. gnavus lacking ΔIbpAB (ΔibpAB R. gnavus: ΔibpAB Rg) by FACS. A 50 μl glycerol stock solution of wild-type Ruminococcus gnavus (JCM6515T) or ΔibpAB Ruminococcus gnavus (described in Patent Document 1) was suspended in 5 ml of GAM medium (Nissui) and cultured for 16 to 24 hours at 37°C under an anaerobic environment in an Anaeropack or anaerobic chamber (Bactron 300). The cells were collected by centrifugation at 8000 rpm and 4°C for 5 minutes and then washed three times with PBS. After the third centrifugation, the cells were suspended in PBS, adjusted to an OD of 1.0 / mL, and dispensed. The tubes into which the aliquots had been dispensed were centrifuged at 8000 rpm at 4°C for 5 minutes, the supernatant was removed, and the pellet was stored at -80°C until use.
[0051] The bacterial pellet prepared by the above bacterial culture was suspended in 1 ml of PBS, and the OD was measured (Yamato Picoexplorer). OD = 1.0 = 8 x 10 bacteria 8 Calculate as 1 x 10 8The suspension was transferred to a new 1.5 ml tube. 2% BSA (Jacson Immuno Research Bovine Serum Albumin (IgG-Free, Protease-Free)) / PBS solution was added to make a total volume of 1 ml of bacterial suspension (1 × 10 8 / ml) was prepared and blocked at room temperature for 15 minutes.
[0052] Add 100 μl (1 × 10) of the appropriate amount of sample to a 1.5 ml tube for measurement. 7 The supernatant was removed, and one of the following antibodies was added: hybridoma supernatant; isotype control (negative control) (Invitrogen Rat IgG Isotype Control (2.5 mg / ml)) diluted 1:250 in 2% BSA PBS; or isotype control (negative control) (BD Pharmingen Purified Rat IgM, k Isotype Control (0.5 mg / ml)) diluted 1:250 in 2% BSA PBS. The mixture was then incubated at 4°C for 30 minutes. 1 ml of PBS was added, and the mixture was centrifuged at 14,000 rpm at 4°C for 5 minutes, after which the supernatant was removed. This step was repeated two more times for a total of three washes.
[0053] The following secondary antibodies were added: Invitrogen Alexa Fluor 488 goat anti-rat IgG (H+L) (2 mg / ml) diluted 1:500 in 2% BSA PBS, or Biolegend Alexa Fluor 488 anti-rat IgM (0.5 mg / ml) diluted 1:250 in 2% BSA PBS. The mixture was incubated in the dark for 30 minutes at 4°C. 1 ml of PBS was added, and the mixture was centrifuged at 14,000 rpm at 4°C for 5 minutes. The supernatant was removed. This step was repeated two more times for a total of three washes.
[0054] After adding 400 μl of PBS and vortexing, FACS analysis was performed using a BD Accuri C6 Plus Flow Cytometer to screen for antibodies that bind to WT Rg but not to ΔIbpAB Rg. The resulting data were analyzed using FlowJo (BD Japan).
[0055] The 10 antibody clones obtained above were evaluated by FACS, and it was shown that all clones bound to WT Rg but not to ΔIbpAB Rg.
[0056] (1-2) Evaluation of binding to IbpA C200, IbpA N200, and IbpA CR by ELISA Next, in the ELISA screening, the reactivity to various truncated proteins was examined by ELISA, and clones that showed high reactivity to IbpA C200 but no reactivity to IbpA N200 (amino acids 30 to 229 of WP_105084811.1) or IbpA CR (amino acids 110 to 378 of WP_105084811.1) were selected.
[0057] Protein solutions suspended in PBS at the following ratios: IbpA C200 (396 μg / ml) → 1:80,000 IbpA N200 (384 μg / ml) → 1:80,000 IbpA CR (871 μg / ml) → 1:172,000 100 μl of each solution was added to a 96-well plate (MAXISORP NUNC-IMMUNO PLATE) and incubated overnight at 4°C. The structures of each protein are shown in Figure 1.
[0058] After overnight incubation, the plate was washed three times with 200 μl of 0.05% Tween 20 in PBS, and 100 μl of 5% skim milk (Wako Skim Milk Powder) in PBS was added. The plate was incubated for 1 hour at room temperature. After removing the solution, the following samples or control antibodies were added: 50 μl of each hybridoma supernatant; and 50 μl of negative control antibody: Rat IgG (25 mg / ml) diluted 1:100, 1:1000, or 1:10,000 in hybridoma culture medium (RPMI). The plate was then incubated for 2 hours at room temperature.
[0059] The plate was washed three times with 200 μl of PBS-T, and after removing the solution, 100 μl of the following diluted HRP antibody solution was added: Rat IgG HRP (Invitrogen) Goat anti-Rat IgG (H+L) Secondary Antibody HRP (0.8 mg / ml), and the plate was then incubated at room temperature for 1 hour.
[0060] The plate was washed three times with 200 μl of PBS-T, and 100 μl of TMB (a 1:1 mixture of Seracare KPL TMB Peroxidase Substrate and Seracare KPL Peroxidase Substrate Solution B) was added. The plate was then incubated in the dark at room temperature for 15 minutes. 100 μl of seracare KPL Stop Solution was added, and the readings were measured at 450 and 620 nm using a plate reader.
[0061] As a result, 27 clones were selected.
[0062] (1-3) Verification of the inhibitory effect on histamine production by LAD2 cells Finally, the inhibitory effect on histamine production was examined.
[0063] Human mast cell line LAD2 cells were cultured at 1 × 10 in StemPro-34 SFM (1×) (Gibco) containing L-glutamine (2 mM) (GIBCO), penicillin (100 U / ml) / streptomycin (100 μg / ml) (GIBCO, recombinant human SCF (Peprotech) (100 ng / ml)). 5 Cells were seeded in a 96-well plate at 100 cells / well and sensitized with purified native human IgE protein (Abcam ab65866) at a final concentration of 10 μg / ml for 2 hours at 37°C under 5% CO2.
[0064] In a 1.5 ml tube, 100 μl of medium, hybridoma supernatant, or human IgG isotype control antibody (final concentration 5 μg / ml) was added to Ibp protein (final concentrations: IbpA: 2.4 μg / ml, IbpB: 2.1 μg / ml, total Ibp protein: 4.5 μg / ml) or IbpA C200 (final concentration 1.5 μg / ml) and incubated at 37°C during sensitization. These pre-incubated samples were added to the sensitized cells and incubated for 2 hours at 37°C under 5% CO2. Cells and culture medium were collected from each well and centrifuged at 3000 rpm at 4°C for 5 minutes to separate the cells from the culture supernatant.
[0065] The amount of degranulated histamine in the culture supernatant was evaluated using a histamine enzyme immunoassay (HIA) (BECKMAN COULTER: IM2015).
[0066] The inhibitory effect varied depending on the clone, and the top eight hybridomas with the highest inhibitory effect, as well as two hybridomas with unique characteristics to be used as comparative antibodies in future studies, were selected, and a total of 10 hybridomas (clone Nos. 1 to 10) were finally cloned.
[0067] Example 2: Examination of the effect of neutralizing antibodies on the binding of human IgE to Ibp in vitro In this example, the 10 antibody clones obtained in Example 1 were examined to determine whether they had neutralizing antibody activity against the binding of human IgE to Ibp in vitro.
[0068] To select an antibody with a stronger inhibitory effect from the 10 monoclonal antibodies prepared in Example 1, in vitro histamine production was examined using a human mast cell line (LAD2 cells). The human mast cell line LAD2 cells were cultured at 1 x 10 in StemPro-34 SFM (1x) (Gibco) (L-glutamine (2 mM) (GIBCO), penicillin (100 U / ml) / streptomycin (100 μg / ml) (GIBCO, recombinant human SCF (Peprotech) (100 ng / ml)). 5 Cells were seeded at 100 μl / well in a 96-well plate. Purified native human IgE protein (Abcam ab65866) was added to the cells at a final concentration of 10 μg / ml and sensitized for 2 hours at 37°C under 5% CO2. In a 1.5 ml tube, 100 μl of medium, hybridoma supernatant (diluted with medium to an antibody concentration of 50 ng / ml), and Ibp proteins (final concentrations of IbpA: 2.4 μg / ml, IbpB: 2.1 μg / ml, total Ibp protein: 4.5 μg / ml) were added and incubated at 37°C during sensitization. These pre-incubated samples were then added to the sensitized cells and incubated for 2 hours at 37°C under 5% CO2. The cells and culture medium were harvested from each well and centrifuged at 3000 rpm at 4°C for 5 minutes to separate the cells from the culture supernatant. The amount of degranulated histamine in the culture supernatant was evaluated using a histamine enzyme immunoassay (HIA) (BECKMAN COULTER: IM2015).
[0069] The results showed that the antibody from Clone A had the strongest inhibitory effect (Figure 2). Furthermore, No. 5 (hereafter referred to as Clone B) was selected because it produced the highest amount of antibody into the medium among the 10 clones and the antibody subclass was IgG. The antibody subclasses of Clone A and Clone B were as follows:
[0070]
[0071] Example 3: Examination of the effect of anti-Ibp antibodies on inhibiting the binding of human IgE to Ibp in vivo In this example, a study was conducted using SPF mice to examine whether antibody Clone A, selected based on the in vitro study in Example 2, also exhibits an inhibitory effect on allergic reactions in vivo.
[0072] An outline of the experimental procedure is shown in Figure 3. BALB / cA mice were divided into two groups of three. The test group received intravenous administration of Clone A anti-Ibp antibody in PBS at 4 mg / kg (equivalent to 100 μg / mouse) via the tail vein. One day later (24 hours later), a mixture of IbpA and IbpB dissolved in PBS (2.5 μg IbpA + 2.5 μg IbpB / mouse) was administered via the tail vein (anti-Ibp antibody-Ibp group). Control mice received 100 μl of PBS alone without Clone A anti-Ibp antibody, followed 24 hours later by the same amount of Ibp protein as the test group (PBS-Ibp group).
[0073] For mice in each group, rectal temperature was measured using a data logger (AND AD-1687) before administration of Ibp protein (indicated as 0 minutes in the graph) and 5, 15, 30, 45, and 60 minutes after administration to determine whether a decrease in rectal temperature occurred in the mice due to an allergic reaction.
[0074] The results are shown in Figure 4. In the control PBS-treated group, administration of Ibp protein caused anaphylactic shock and a drop in rectal temperature. On the other hand, in the antibody-treated group (anti-Ibp antibody-Ibp group), the drop in rectal temperature was alleviated, and the allergic reaction was suppressed (Figure 4).
[0075] Example 4: Sequence analysis of antibodies that inhibit the binding of human IgE to Ibp In this example, the anti-Ibp antibody Clone A, selected based on the in vitro studies in Example 2, was sequenced to examine the regions important for antigen binding.
[0076] Cell preparation for antibody sequence analysis Clone A hybridoma cells were cultured in a non-coated culture flask using hybridoma culture medium prepared by mixing the following reagents: RPMI Medium 1640 (x1): 500 ml, FBS (heat inactivated) (Gibco): 50 ml, Penicillin-Streptomycin-Glutamine (100x) (Gibco): 5.5 ml, and Sodium Pyruvate (100 mM) (Gibco): 5.5 ml. The hybridoma culture medium was centrifuged (1000 rpm / 5 min), the supernatant was removed, and the cells were suspended in PBS. The cell number was counted and determined to be 2 x 10 6 The cells were centrifuged again, the supernatant was removed, and the pellet was suspended in a storage solution for sending to an analytical laboratory.
[0077] For antibody sequence analysis, the hybridoma cells prepared as described above were sent to an analytical institution (Biopeak Co., Ltd.) for sequence analysis.
[0078] The determined amino acid sequence of the antibody variable region is as follows: In this sequence, the underlined portion indicates the complementarity-determining region (CDR), which is the binding site between Ibp and the antibody.
[0079] VH amino acid sequence: EVMLVESGGG LVQPGRSMKL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNAKSTLY LQMNSLRSED TATYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 7) VL amino acid sequence: DIQMTQSPAS LSASLEEIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTQ YSLKISRLQV EDIGIYYCLQ AYSAPWTFGG GTKLELK (SEQ ID NO: 8)
[0080] Example 5: Preparation of humanized antibodies In this example, humanized antibodies were prepared based on the antibody Clone A sequenced in Example 4.
[0081] The humanized antibodies were produced by CDR-grafting (CDR-grafting) of the heavy chain complementarity-determining regions (CDR1, GFTFSNYGMA, SEQ ID No.: 1), CDR2 (TISYDGSSTYYRDSVKG, SEQ ID No.: 2), and CDR3 (ESFGTTVVPHYFDY, SEQ ID No.: 3) of the donor monoclonal antibody Clone A, the sequences of which were confirmed in Example 4, and the light chain complementarity-determining regions (CDR1, QASQDIGNWLS, SEQ ID No.: 4), CDR2 (GATSLAD, SEQ ID No.: 5), and CDR3 (LQAYSAPWT, SEQ ID No.: 6), using the framework region (FR) of a human antibody as an acceptor.
[0082] Subsequently, based on sequence analysis, computational modeling, and antigen / antibody structural information, we designed back mutations in the FRs to create antibody derivatives in which mutations were introduced into non-conserved positions within the FRs of the humanized antibody.
[0083] Using this procedure, three heavy chain variable region VH domains and three light chain variable region VL domains were constructed, each with the amino acid sequences shown below. The underlined portions in these sequences indicate the complementarity-determining regions (CDRs), which are the binding sites between Ibp and the antibody.
[0084] Humanized VH domain (HuVHv1): QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 9); Humanized VH domain (HuVHv2): QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRSED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 10); Humanized VH domain (HuVHv3): QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 11); Humanized VL domain (HuVLv1): DIQMTQSPSS LSASVGDRVT ITCQASQDIG NWLSWYQQKP GKSPKLLIYG ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 12); Humanized VL domain (HuVLv2): DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 13); Humanized VL domain (HuVLv3): DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTQ YTLTISSLQP EDIATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 14).
[0085] In this example, these three types of heavy chain variable region VH domains and three types of light chain variable region VL domains were arbitrarily combined to produce nine types of humanized antibodies (i.e., hClone A_H1L1 (HuVHv1×HuVLv1); hClone A_H1L2 (HuVHv1×HuVLv2); hClone A_H1L3 (HuVHv1×HuVLv3); hClone A_H2L1 (HuVHv2×HuVLv1); hClone A_H2L2 (HuVHv2×HuVLv2); hClone A_H2L3 (HuVHv2×HuVLv3); hClone A_H3L1 (HuVHv3×HuVLv1); hClone A_H3L2 (HuVHv3×HuVLv2); hClone A_H3L3 (HuVHv3 × HuVLv3) was generated.
[0086] Using these antibodies, hClone A_H1L1 and hClone A_H3L1 were used as examples to measure the binding affinity of the antibodies to IbpB protein using surface plasmon resonance (SPR). The antibodies were captured on a Protein A chip surface at a capture level of approximately 300 RU. Then, various concentrations (listed in Table 2) of the analyte (IbpB protein) diluted in running buffer were injected for affinity and kinetic measurements. Using a 1:1 binding model, the association rate constant (ka, 1 / Ms) and dissociation rate constant (kd, 1 / s) were measured. Based on these values, the dissociation constant KD (M) was calculated according to the equation KD = kd / ka, and the binding affinity was calculated. The binding affinity was similarly measured and calculated using Clone A antibody and Clone A_hIgG1 antibody as controls.
[0087] The measured binding affinities are shown in Table 2. As a result, it was revealed that the obtained humanized antibody has strong affinity for the IbpB protein.
[0088]
[0089] Based on the previous finding that in vivo allergic reactions can be prevented by substances that bind not directly to IgE but to a region important for IgE binding in the Ibp protein of Lachnospiraceae bacteria (e.g., Ruminococcus bacteria), an enterobacterium associated with allergic diseases, the present invention provides an antibody or antibody derivative that binds to the Ibp protein of Lachnospiraceae bacteria or a variant thereof and can prevent or treat in vivo allergic reactions. The antibody or antibody derivative can suppress allergic reactions by exerting an inhibitory effect on allergens. Therefore, it does not bind to human IgE and suppresses allergic reactions without inhibiting the host's immune system, thereby reducing the problem of side effects.
Claims
1. (1) An antibody or antibody derivative having binding activity to an Ibp antigen, comprising the heavy chain complementarity determining regions, CDR1 (GFTFSNYGMA, SEQ ID No.: 1), CDR2 (TISYDGSSTYYRDSVKG, SEQ ID No.: 2), and CDR3 (ESFGTTVVPHYFDY, SEQ ID No.: 3), and the light chain complementarity determining regions, CDR1 (QASQDIGNWLS, SEQ ID No.: 4), CDR2 (GATSLAD, SEQ ID No.: 5), and CDR3 (LQAYSAPWT, SEQ ID No.: 6).
2. The antibody or antibody derivative of claim 1, wherein the antibody or antibody derivative is human.
3. The antibody or antibody derivative of claim 2, wherein the human antibody derivative is selected from a human antibody variant or a functional fragment thereof selected from a humanized antibody, a chimeric antibody, a multivalent antibody, and a multispecific antibody.
4. The antibody or antibody derivative of claim 3, wherein the functional fragment is a Fab, Fab', F(ab')2, single chain variable region fragment (scFv) or disulfide stabilized (dsFv) antibody.
5. The amino acid sequence of the heavy chain variable region VH domain of an antibody or human antibody derivative having binding ability to an Ibp antigen is the amino acid sequence of (VH-1-1) EVMLVESGGG LVQPGRSMKL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNAKSTLY LQMNSLRSED TATYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 7), or an amino acid sequence of SEQ ID NO: 7 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3); (VH-1-2) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA an amino acid sequence of PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: 9), or an amino acid sequence of SEQ ID NO: 9 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3); (VH-1-3) QVQLVESGGG VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PTKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRSED TAVYYCTRES FGTTVVPHYF DYWGQGTLVT VSS (SEQ ID NO: or an amino acid sequence of SEQ ID NO: 10 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion of the amino acid sequence of SEQ ID NO: 10 other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3); (VH-1-4) QVQLVESGGGThe antibody or antibody derivative of claim 1 or 2, wherein the antibody or antibody derivative is selected from the group consisting of the amino acid sequence of VVQPGRSLRL SCAASGFTFS NYGMAWVRQA PGKGLEWVAT ISYDGSSTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRES FGTTVVPHYF DYWGQGVMVT VSS (SEQ ID NO: 11), or an amino acid sequence of SEQ ID NO: 11 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3).
6. The amino acid sequence of the light chain variable region VL domain of an antibody or human antibody derivative having binding ability to an Ibp antigen is the amino acid sequence of (VL-1-1) DIQMTQSPAS LSASLEEIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPS RFSGSRSGTQ YSLKISRLQV EDIGIYYCLQ AYSAPWTFGG GTKLELK (SEQ ID NO: 8), or an amino acid sequence of the amino acid sequence of SEQ ID NO: 8 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); (VL-1-2) DIQMTQSPSS LSASVGDRVT ITCQASQDIG NWLSWYQQKP GKSPKLLIYG an amino acid sequence of ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 12), or an amino acid sequence of SEQ ID NO: 12 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); (VL-1-3) DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG an amino acid sequence of ATSLADGVPS RFSGSRSGTD YTLTISSLQP EDFATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 13), or an amino acid sequence of SEQ ID NO: 13 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); an amino acid sequence containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6); (VL-1-4) DIQMTQSPSS LSASVGDIVT ITCQASQDIG NWLSWYQQKP GKSPQLLIYG ATSLADGVPSThe antibody or antibody derivative of claim 1 or 2, wherein the antibody or antibody derivative is selected from the group consisting of the amino acid sequence of RFSGSRSGTQ YTLTISSLQP EDIATYYCLQ AYSAPWTFGG GTKVELK (SEQ ID NO: 14), or an amino acid sequence of SEQ ID NO: 14 containing one or several amino acid substitutions (e.g., conservative substitutions), insertions, or deletions in a portion other than CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6).
7. An antibody or antibody derivative according to any one of claims 1 or 2, which binds to Ibp and inhibits the binding of Ibp to IgE in vivo.
8. The antibody or antibody derivative according to claim 7 for preventing or treating an allergic disease.
9. The antibody or antibody derivative according to claim 8, wherein the allergic disease is atopic dermatitis.
10. (1) A pharmaceutical composition for preventing or treating an allergic disease, comprising an antibody or antibody derivative having binding affinity to an Ibp antigen, the antibody or antibody derivative comprising the heavy chain and light chain complementarity determining regions, CDR1 (GFTFSNYGMA, SEQ ID No.: 1), CDR2 (TISYDGSSTYYRDSVKG, SEQ ID No.: 2), and CDR3 (ESFGTTVVPHYFDY, SEQ ID No.: 3), and the light chain complementarity determining regions, CDR1 (QASQDIGNWLS, SEQ ID No.: 4), CDR2 (GATSLAD, SEQ ID No.: 5), and CDR3 (LQAYSAPWT, SEQ ID No.: 6).
11. The pharmaceutical composition for preventing or treating an allergic disease according to claim 10, wherein the antibody or antibody derivative is human.
12. A pharmaceutical composition for preventing or treating an allergic disease according to claim 11, wherein the allergic disease is atopic dermatitis.
Citation Information
Patent Citations
Detection of FGFR2
WO2016171107A1
Antibody recognizing extracellular region of ALK2 / acvr1
WO2021020282A1
Establishment of therapy and diagnosis for allergic diseases through control of immunoglobulin-binding protein
WO2023100977A1
